Arlington Partners’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-4,854
| Closed | -$280K | – | 13 |
|
|
2026
Q2 | $280K | Buy |
4,854
+877
| +22% | +$50.4K | 0.51% | 18 |
|
|
2026
Q1 | $241K | Buy |
+3,977
| New | +$232K | 0.48% | 24 |
|
|
2025
Q4 | – | Sell |
-105,711
| Closed | -$4.77M | – | 11 |
|
|
2025
Q3 | $4.77M | Buy |
105,711
+10,382
| +11% | +$485K | 1.65% | 42 |
|
|
2025
Q2 | $4.41M | Buy |
95,329
+14,532
| +18% | +$713K | 1.63% | 35 |
|
|
2025
Q1 | $4.93M | Hold |
80,797
| – | – | 1.93% | 6 |
|
|
2024
Q4 | $4.57M | Sell |
80,797
-10,000
| -11% | -$559K | 1.77% | 6 |
|
|
2024
Q3 | $4.7M | Buy |
90,797
+12,491
| +16% | +$586K | 1.84% | 5 |
|
|
2024
Q2 | $3.25M | Buy |
78,306
+15,773
| +25% | +$706K | 1.61% | 26 |
|
|
2024
Q1 | $3.39M | Buy |
62,533
+60,558
| +3,066% | +$3.08M | 1.73% | 13 |
|
|
2023
Q4 | $101K | Buy |
+1,975
| New | +$104K | 0.03% | 102 |
|
|
2023
Q3 | – | Sell |
-1,692
| Closed | -$108K | – | 384 |
|
|
2023
Q2 | $108K | Sell |
1,692
-182
| -10% | -$12.2K | 0.02% | 236 |
|
|
2023
Q1 | $130K | Sell |
1,874
-317
| -14% | -$22.4K | 0.02% | 170 |
|
|
2022
Q4 | $158K | Buy |
2,191
+404
| +23% | +$30.5K | 0.03% | 109 |
|
|
2022
Q3 | $127K | Sell |
1,787
-172
| -9% | -$12.5K | 0.05% | 116 |
|
|
2022
Q2 | $151K | Buy |
1,959
+643
| +49% | +$49K | 0.05% | 119 |
|
|
2022
Q1 | $96K | Buy |
1,316
+74
| +6% | +$4.97K | 0.03% | 183 |
|
|
2021
Q4 | $77K | Sell |
1,242
-1,019
| -45% | -$59.8K | 0.02% | 230 |
|
|
2021
Q3 | $134K | Buy |
2,261
+1,579
| +232% | +$104K | 0.04% | 146 |
|
|
2021
Q2 | $46K | Hold |
682
| – | – | 0.02% | 201 |
|
|
2021
Q1 | $43K | Hold |
682
| – | – | 0.02% | 257 |
|
|
2020
Q4 | $42K | Hold |
682
| – | – | 0.02% | 113 |
|
|
2020
Q3 | $41K | Hold |
682
| – | – | 0.02% | 107 |
|
|
2020
Q2 | $40K | Buy |
682
+593
| +666% | +$35.5K | 0.02% | 110 |
|
|
2020
Q1 | $5K | Sell |
89
-400
| -82% | -$24.4K | ﹤0.01% | 182 |
|
|
2019
Q4 | $31K | Buy |
489
+89
| +22% | +$5.1K | 0.02% | 151 |
|
|
2019
Q3 | $20K | Hold |
400
| – | – | 0.01% | 139 |
|
|
2019
Q2 | $18K | Sell |
400
-1,169
| -75% | -$54.5K | 0.01% | 181 |
|
|
2019
Q1 | $75K | Buy |
1,569
+169
| +12% | +$8.42K | 0.05% | 106 |
|
|
2018
Q4 | $73K | Buy |
1,400
+400
| +40% | +$21.5K | 0.05% | 102 |
|
|
2018
Q3 | $62K | Buy |
+1,000
| New | +$59.3K | 0.04% | 118 |
|
Other funds holding BMY
Arlington Partners's BMY Position: Q3 2026 in Review
Arlington Partners sold out of Bristol-Myers Squibb (BMY) in Q3 2026, closing a stake of 4,854 shares — an estimated $280K sold.
Arlington Partners first reported a position in BMY in Q3 2018 and held it in 30 quarters. The position peaked at $4.93M in Q1 2025. 762 funds tracked by Wall St. Rank hold BMY as of Q3 2026.
- Arlington Partners reported no remaining Bristol-Myers Squibb position as of Q3 2026 after selling out during the quarter.
- Arlington Partners sold 4,854 Bristol-Myers Squibb shares in Q3 2026, an estimated $280K.
- Arlington Partners first reported a position in Bristol-Myers Squibb in Q3 2018 and held it in 30 quarters.
- Arlington Partners's Bristol-Myers Squibb position peaked at $4.93M in Q1 2025.
- 762 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.
Based on Arlington Partners's 13F filing for Q3 2026, filed 20 Oct 2026.